In this week’s episode, host Mike Moore speaks with Lloyd Diamond, CEO Pixium Vision, about their technology that focuses on bionic vision for those who have lost their sight.Pixium Vision utilizes the latest advancements in visual processing, micro-electronics, optoelectronics, neurobiology, and intelligent software algorithms to create Bionic Vision Systems. By leveraging their expertise in machine brain interface and artificial intelligence, Pixium Vision aims to develop these systems to address severe vision loss and enhance the autonomy, movement, and overall well-being of individuals affected by retinal degenerative diseases.Today, Mike and Lloyd discuss Pixium Vision's bionic vision technology, which aims to restore sight for visually impaired individuals. Lloyd explains the company's background, their first-generation technology called Iris, and their second-generation technology called Prima. He demonstrates how the technology allows patients to read a weather forecast and identifies basic features using the glasses. They also discuss the surgical process, the uniqueness of Pixium Vision's technology, and their regulatory status.Notable Quotes“Basically, we're targeting dry AMD. Dry AMD is a disease where the photoreceptor cells no longer function, what we do is we create a small incision in the retina, and we inject our premier implant in the subretinal space, we apply gas or oil to reattach the retina.”- Lloyd (05:23)“I think as humans inherent in the cellular level of the retina, we can see red, green, and blue, but then everything else is learned. When you're a kid, the teacher says, Oh, this is yellow. And now you learn that that's yellow. So inherent in the retina is only red, green, and blue.” - Lloyd (12:22) In This Episode(01:59) The origin story of Pixium Vision(05:11) The technology behind Pixium Vision's product(10:30) How a legally blind patient can read a weather forecast using bionic vision technology(12:20) The ability to enhance contrast and identify facial traits(14:53) The target indications and market potential(21:27) Detaching the retina and surgical training(23:10) Advancements in implant technology(26:59) Regulatory progress and commercialization plans(32:26) The company's investment and future plans(33:26) Clarity on the investment process(33:48) Classification of investmentsOur GuestLloyd Diamond is the CEO of Pixium Vision. He has 25 years of experience in medtech, leading disruptive technology commercialization in life sciences. He successfully penetrated markets in Europe and the US, including a NASDAQ IPO. He holds dual degrees in Biochemistry and Marketing and an MBA.

Resources & Links
LinkedIn: Mike Moore
LinkedIn: The Bleeding Edge of Digital Health